home / stock / okyo / okyo news

OKYO News and Press, OKYO Pharma Limited

Stock Information
Company Name: OKYO Pharma Limited
Stock Symbol: OKYO
Market: NASDAQ
Website: okyopharma.com
Menu
OKYO OKYO Quote OKYO Short OKYO News OKYO Articles OKYO Message Board
Get OKYO Alerts

News, Short Squeeze, Breakout and More Instantly...
OKYO - OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress

LONDON and NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that its abstract has...
OKYO - Overweight Recommendation Issued On OKYO By Piper Sandler

2026-02-20 05:15:05 ET Piper Sandler analyst issues OVERWEIGHT recommendation for OKYO on February 20, 2026 10:06AM ET. OKYO was trading at $1.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy re...

OKYO - OKYO Pharma prices public offering at $1.85/share to raise up to $20M

2026-02-13 02:02:27 ET OKYO Pharma Limited ( OKYO ) has announced a public offering of 10,815,000 ordinary shares priced at $1.85 each.... Read the full article on Seeking Alpha For further details see: OKYO Pharma prices public offering at $1.85/share to rai...

OKYO - OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares

LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the pricing of an und...
OKYO - OKYO Pharma launches underwritten public offering of ordinary shares

2026-02-12 16:13:15 ET More on OKYO Pharma Seeking Alpha’s Quant Rating on OKYO Pharma Historical earnings data for OKYO Pharma Financial information for OKYO Pharma Read the full article on Seeking Alpha For further details see: OKYO Pharm...

OKYO - OKYO Pharma Announces Public Offering of Ordinary Shares

LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:  OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it intends ...

OKYO - OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:  OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that it has tran...
OKYO - OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer

Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease Dr. Mantelli will lead the clinical and regulatory strategy to advance the company’s dev...

OKYO - OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting

LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that an abstract on i...

OKYO - OKYO Pharma Announces Successful Type C Meeting with the FDA

LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq:  OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that it held a s...
Next 10